PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Mitochondrial and cellular

Epithalon

Also written as: Epitalon, Epithalone, Ala-Glu-Asp-Gly, AEDG peptide

Epithalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) made in Russia as a stand-in for a cattle pineal-gland extract; the evidence is mostly cell and animal work from one research group, and no adequate human trial has shown it treats anything.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • Epithalon is a synthetic peptide of four amino acids, modelled on epithalamin, an extract of cattle pineal glands. It is not an approved medicine in the US or the EU.
  • Almost all of the research comes from Vladimir Khavinson's group in St Petersburg and its collaborators, much of it published in Russian journals.
  • In human cells grown in the lab it switched on telomerase and lengthened telomeres. An independent London group reported similar results in 2025, including in cancer cells.
  • The well-known reports of fewer deaths among elderly people used the cattle extract epithalamin, not epithalon. No adequately powered randomised trial has shown epithalon treats any condition.
  • The FDA found no clinical studies assessing its safety in people, and warned that long-term telomere lengthening could in theory favour cancer.
  • FDA staff advised against pharmacy compounding in May 2026. In October 2026 a draft, non-binding HHS policy said it would tolerate limited compounding of injectable epitalon acetate under strict conditions.
  • It is not named on the anti-doping Prohibited List, but class S0 covers substances with no government approval for human use, and no approval for it was found.

What it is

Epithalon (also spelled epitalon or epithalone) is a tetrapeptide: a chain of just four amino acids, alanine, glutamic acid, aspartic acid and glycine, often shortened to AEDG. It is made synthetically. It has no official international drug name; "epitalon" is a common name, which the FDA says has been used for different salts and products.

More on what it is and where it came from

It was designed as a simple, synthetic version of epithalamin, a mixture of peptides extracted from the pineal glands of cattle. The pineal gland is a small gland in the brain that makes melatonin, the hormone linked to the sleep-wake cycle. The FDA treats epithalon and epithalamin as different substances, which matters because much of the human research that is quoted for epithalon actually used epithalamin.

It is sold as the plain peptide (free base) or as an acetate salt. The FDA notes that most published studies do not say which form they used.

Epithalon came out of Professor Vladimir Khavinson's work on pineal-gland peptides in St Petersburg, Russia, where his group first studied epithalamin, the cattle pineal extract. The FDA's 2026 review describes epithalon as a synthetic peptide that may be the active component of epithalamin, made partly because calf pineal glands were in short supply. The same review gives two different dates for its first synthesis: the late 1980s in one section and 1999 in another. Most studies since have come from Khavinson's institute and the N.N. Petrov oncology institute in St Petersburg.

How it is thought to work

Nobody has shown how epithalon works in people. In lab cultures of human fetal lung cells, Khavinson's group reported that it switched on telomerase, the enzyme that rebuilds telomeres. Telomeres are protective caps on the ends of chromosomes that shorten each time a cell divides. The group proposed that this explains the longer lifespans seen in some of its animal studies. A 2025 study at Brunel University London found telomere lengthening in normal human cells through telomerase, and in breast-cancer cells through a different route.

More on how it works

In old female rhesus monkeys it raised evening melatonin and lowered evening cortisol, according to the FDA's summary of a 2001 study. But in a laboratory study, adding it to rat pineal glands did not increase melatonin release, so how it might affect melatonin in a living animal is unknown. The FDA found no animal study that measured its effect on sleep.

The FDA pointed out that the telomere effect cuts both ways. Long telomeres have been linked to a higher risk of some cancers, so continuous long-term exposure could in theory help damaged cells avoid the normal ageing process that stops them dividing. This has not been tested.

What is established in people

Very little is established in people. The often-quoted reports of fewer deaths among elderly people (266 people followed for 6 to 8 years, and 79 heart patients) used epithalamin, the cattle pineal extract, not synthetic epithalon, and come from the developer's network with no blinding described. Studies of epithalon itself are small and measured melatonin or eye tests, not health outcomes; the largest randomised one had 40 women, lasted 20 days and did not measure sleep. No randomised, blinded, placebo-controlled trial meeting modern standards has shown that epithalon treats any condition, and the FDA found no studies assessing its safety in people.

What the studies found

12 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2011

    Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up

    Described as a randomised comparative study.

    Full finding, who was studied, and limits

    Who: 79 elderly patients with coronary heart disease and signs of rapid cardiovascular ageing, at the Institute of Gerontology in Kiev: 39 were given epithalamin plus standard treatment over three years, 40 standard treatment alone.

    Described as a randomised comparative study. The authors reported significantly lower mortality with epithalamin, slower cardiovascular ageing, preserved physical endurance and a normalised daily melatonin rhythm. The abstract gives no mortality figures.

    Read with care: Epithalamin, not epithalon. No placebo and no blinding is described. The title speaks of the pituitary gland and a 15-year follow-up, while the abstract describes a pineal preparation given over three years. A 2026 review warns its patients may overlap with an earlier 2006 report from the same team, so it should not be counted as a separate confirmation.

    Bulletin of Experimental Biology and Medicine · pubmed.ncbi.nlm.nih.gov

  2. Human trial2007

    Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people

    Ageing was linked to lower night-time melatonin.

    Full finding, who was studied, and limits

    Who: Old monkeys and elderly people. Numbers and group design are not given in the English abstract.

    Ageing was linked to lower night-time melatonin. The authors reported that both epithalamin and epithalon restored night-time melatonin release and its daily rhythm, mainly in people whose pineal function was low, and stated that the preparations had no side effects.

    Read with care: Only the English abstract is available. It does not say how many people took part, whether there was a placebo group, or how side effects were checked. The FDA could not evaluate the full paper because it is in Russian.

    Advances in Gerontology (Uspekhi Gerontologii), in Russian · pubmed.ncbi.nlm.nih.gov

  3. Human trial2003

    Peptides of pineal gland and thymus prolong human life

    Compared with the control group, the authors reported death rates 1.6 to 1.8 times lower with epithalamin, 2.0 to 2.1 times lower with thymalin and 2.5 times lower with both.

    Full finding, who was studied, and limits

    Who: 266 elderly people followed for 6 to 8 years. During the first 2 to 3 years some received thymalin (a thymus extract), epithalamin (the cattle pineal extract), or both, and were compared with a control group.

    Compared with the control group, the authors reported death rates 1.6 to 1.8 times lower with epithalamin, 2.0 to 2.1 times lower with thymalin and 2.5 times lower with both. In a group given both every year for six years, death rates were 4.1 times lower.

    Read with care: This study used epithalamin, not epithalon; the FDA treats them as different substances. The abstract does not describe randomisation or blinding or give group sizes, and the work comes from the developer. It cannot show that the extracts, rather than differences between the groups, explain the difference in deaths.

    Neuro Endocrinology Letters · pubmed.ncbi.nlm.nih.gov

  4. Human trial2002

    Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa

    In the rats, epithalon was reported to preserve retinal structure and electrical activity.

    Full finding, who was studied, and limits

    Who: Campbell rats with inherited retinal degeneration, and patients with retinitis pigmentosa, an inherited disease that slowly destroys the retina. A 2026 review that read the full paper reports 162 treated patients aged 18 to 72, compared with 46 patients on conventional treatment.

    In the rats, epithalon was reported to preserve retinal structure and electrical activity. In patients, the authors reported a positive clinical effect in 90% of cases.

    Read with care: The abstract gives no patient numbers or design. The 2026 review says randomisation and blinding were not clearly described, there was no placebo, it was a single-centre study and it has not been independently repeated. An FDA orphan-drug designation for retinitis pigmentosa, granted in 2010, was withdrawn in 2016.

    Neuro Endocrinology Letters · pubmed.ncbi.nlm.nih.gov

  5. Review2026

    Evaluation of Epitalon-related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List (FDA briefing document)

    The FDA found no studies of epithalon in people with insomnia and none using injection under the skin.

    Full finding, who was studied, and limits

    Who: The FDA's own review of the published human and animal evidence and the two withdrawn compounding nominations, which proposed injection under the skin for insomnia.

    The FDA found no studies of epithalon in people with insomnia and none using injection under the skin. It identified three human studies: two in night-shift workers given it under the tongue, and the retinitis pigmentosa study. In the main one (Ivko and colleagues, 2021), 40 women aged 40 to 50 with low melatonin output were randomly assigned to epithalon or a salt-water placebo spray for 20 days; a melatonin breakdown product in urine rose 1.7-fold with epithalon and did not change with placebo, but sleep was not measured, blinding was not specified and no safety data were reported. The FDA found no clinical studies assessing safety, no human pharmacokinetic data, and no animal studies of single-dose, repeat-dose, reproductive or two-year cancer toxicity. It proposed that neither epitalon nor epitalon acetate be added to the list pharmacies may compound from.

    Read with care: A regulator's review focused on the nominated use, insomnia. It is the best single summary of the evidence. It notes that most pharmacology studies come from Khavinson's group and that two Russian-language papers could not be evaluated.

    U.S. Food and Drug Administration, dated 12 May 2026, for the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026 · fda.gov

  6. Review2026

    Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence

    Human data were limited to small physiological or biomarker studies and one older controlled study in retinitis pigmentosa, and no adequately powered randomised trial had shown that epithalon works for any condition.

    Full finding, who was studied, and limits

    Who: A narrative review, by US academic physicians, of the published epithalon and epithalamin research up to September 2026.

    Human data were limited to small physiological or biomarker studies and one older controlled study in retinitis pigmentosa, and no adequately powered randomised trial had shown that epithalon works for any condition. The authors found pharmacokinetic, dose-finding and long-term safety data inadequate, noted that the research is concentrated in a small number of groups, and called epithalon "biologically active but clinically unproven".

    Read with care: A narrative review, not a systematic one. One author works at a private clinic; the authors declared no financial interest in epithalon.

    International Journal of Molecular Sciences · pubmed.ncbi.nlm.nih.gov

  7. Animal study2007

    Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes

    Under standard lighting, epithalon did not change lifespan.

    Full finding, who was studied, and limits

    Who: Female rats kept under standard lighting, natural daylight, or constant light. Strain and group sizes are not given in the abstract.

    Under standard lighting, epithalon did not change lifespan. Constant light and natural light both shortened the rats' lives; under those conditions epithalon lengthened maximum lifespan by 24 and 95 days respectively. It reduced spontaneous tumours only under natural light.

    Read with care: From the same research network, with few details in the abstract. It shows the lifespan effect was not consistent: under ordinary lab conditions there was none.

    Bulletin of Experimental Biology and Medicine · pubmed.ncbi.nlm.nih.gov

  8. Animal study2003

    Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

    Epithalon did not change food intake, body weight or average lifespan.

    Full finding, who was studied, and limits

    Who: Female outbred Swiss-derived SHR mice, 54 per group, given epithalon or salt-water injections in repeated short courses from age 3 months until natural death.

    Epithalon did not change food intake, body weight or average lifespan. The longest-lived 10% of mice lived 13.3% longer and the maximum lifespan was 12.3% longer. Overall tumour rates did not change, but leukaemia was 6.0 times less common. Chromosome damage in bone-marrow cells was 17.1% lower. The authors concluded it appeared safe for long-term use in mice.

    Read with care: One strain, females only, from the developer's group. The FDA noted that only one dose was tested and that the total treatment time was far shorter than the two years a standard cancer study requires, so it cannot rule out a cancer risk from continuous use.

    Biogerontology · pubmed.ncbi.nlm.nih.gov

  9. Animal study2002

    Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

    Epithalon-treated mice had fewer and smaller breast tumours in total than controls (p<0.05), and HER-2/neu gene activity in their tumours was 3.7 times lower.

    Full finding, who was studied, and limits

    Who: Female FVB/N HER-2/neu transgenic mice, which are bred to develop breast tumours, compared with a salt-water group and a group given another peptide (Vilon). Italian researchers were among the co-authors.

    Epithalon-treated mice had fewer and smaller breast tumours in total than controls (p<0.05), and HER-2/neu gene activity in their tumours was 3.7 times lower.

    Read with care: Group sizes are not given in the abstract. A mouse model of a single cancer type; it does not show that epithalon prevents cancer in people.

    International Journal of Cancer · pubmed.ncbi.nlm.nih.gov

  10. Cell study2025

    Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

    In normal cells, telomeres lengthened as the amount of epithalon increased, together with more telomerase gene activity (hTERT) and telomerase activity.

    Full finding, who was studied, and limits

    Who: Two human breast-cancer cell lines (21NT and BT474) and normal human epithelial cells and fibroblasts, studied at Brunel University London, a group not connected to the developer.

    In normal cells, telomeres lengthened as the amount of epithalon increased, together with more telomerase gene activity (hTERT) and telomerase activity. In the cancer cells, telomeres also lengthened, but through a telomerase-independent route called ALT (alternative lengthening of telomeres). This is the main independent repeat of the 2003 telomere finding.

    Read with care: Cell lines only. A correction was published in November 2025; a 2026 review reports that it replaced several figures. That telomeres also lengthened in cancer cells is a reason for caution, not reassurance.

    Biogerontology · pubmed.ncbi.nlm.nih.gov

  11. Cell study2003

    Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

    Adding epithalon increased production of the working part of telomerase, increased telomerase activity, and lengthened telomeres.

    Full finding, who was studied, and limits

    Who: Cultures of human fetal fibroblasts (connective-tissue cells) that normally have no telomerase activity. The FDA review describes them as fetal lung fibroblasts.

    Adding epithalon increased production of the working part of telomerase, increased telomerase activity, and lengthened telomeres. The authors suggested the peptide could reactivate the telomerase gene in ordinary body cells, with possible effects on the lifespan of cells and of the whole organism.

    Read with care: Cells in a dish, in a short report from the developer's own group. The abstract does not say how many experiments were run. Longer telomeres in cultured cells do not show any benefit in a person.

    Bulletin of Experimental Biology and Medicine · pubmed.ncbi.nlm.nih.gov

  12. Cell study2003

    Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-GLy) on melatonin secretion by the pineal gland of young and old rats

    Epithalon had no significant effect on melatonin release from the glands of either age, and did not change the rise in melatonin caused by a stimulating drug (isoproterenol).

    Full finding, who was studied, and limits

    Who: Pineal glands removed from young (9-week-old) and old (27-month-old) male Wistar rats and kept alive in a flow chamber, at a Paris laboratory. Khavinson and Anisimov were co-authors.

    Epithalon had no significant effect on melatonin release from the glands of either age, and did not change the rise in melatonin caused by a stimulating drug (isoproterenol).

    Read with care: Isolated tissue, not living animals; group sizes are not given in the abstract. It suggests any effect on melatonin in the body is not a direct action on the pineal gland, but the real mechanism is unknown.

    Journal of Endocrinological Investigation · pubmed.ncbi.nlm.nih.gov

Safety findings

  • The FDA found no clinical studies assessing the safety of epithalon in people, and no data on how the body absorbs, spreads or clears it. Source: fda.gov
  • In the 20-day study in 20 women given epithalon under the tongue, no safety data were reported. A Russian-language abstract states that pineal preparations had "no side effects" in elderly people, but gives no details of how many people took part or how side effects were checked. Source: fda.gov
  • No animal studies of single-dose or repeat-dose toxicity, effects on pregnancy, or two-year cancer risk were found. The two chromosome-damage studies in mice tested only one dose, with four animals per group. Source: fda.gov
  • Possible cancer risk: the FDA wrote that because epithalon appears to activate telomerase and lengthen telomeres, continuous long-term exposure could in theory help cells evade the normal limits on division and become cancerous. A 2025 cell study also found telomere lengthening in breast-cancer cell lines. This has not been tested in people. Source: fda.gov
2 more safety findings
  • The FDA's side-effect database held no reports for epithalon up to 5 December 2025. The FDA states that an absence of reports does not mean a substance is safe. Source: fda.gov
  • The FDA says injected epithalon may carry a risk of unwanted immune reactions because of possible clumping (aggregation) of the peptide and peptide-related impurities, and that it lacks enough information to know whether it would cause harm. Source: fda.gov

Rules and status

Not approved. Epithalon is not an FDA-approved medicine or part of one, and the FDA found no approved product containing it in the EU or in the ten other countries it checked.

The full history, with dates

Epitalon was placed in Category 2 of the FDA's interim compounding policy (nominated substances that may present significant safety risks) on 29 September 2023. The two nominations, from Wells Pharmacy Network and from LDT Health Solutions on behalf of the International Peptide Society, were withdrawn. The FDA page current as of 22 April 2026 lists epitalon under "nominated but withdrawn", with the stated reason: "Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans." The FDA category list updated 14 May 2026 does not list it in any category. The FDA reviewed it anyway: its briefing document of 12 May 2026 proposed not adding epitalon or epitalon acetate to the list pharmacies may compound from, and the advisory committee discussed it on 24 July 2026; according to HHS, the committee voted in favour of inclusion. On 30 October 2026 HHS published notice of a draft, interim and non-binding enforcement-discretion policy, and epitalon is one of the six peptides in its Appendix A. Appendix B gives HHS's reasoning as threefold: newer certificates from FDA-registered facilities supply the endotoxin, microbial, residual-solvent, solubility and elemental-impurity results the FDA found missing; historical use is now documented and quantified; and the FDA's safety concerns are "mechanistic rather than based on observed harm", the limited controlled human exposure reported no side effects, and documented use is in intermittent courses. The policy covers only epitalon acetate, as injections under the skin or into muscle dispensed in intermittent courses, made from ingredient with a qualifying certificate of analysis. Other conditions include an FDA-registered original manufacturer following good manufacturing practice, a single active ingredient per product, reporting of serious adverse events to FDA MedWatch, the label statement "This is a compounded drug product. Not for resale.", a patient-specific prescription, and only an FDA-cleared syringe as the delivery device. HHS may revisit the policy if a safety or quality problem arises. It is not FDA approval, and the FDA's final decision on the 503A list was still pending; no final version of the policy was found. Separately, an FDA orphan-drug designation for retinitis pigmentosa granted in 2010 was withdrawn in 2016. No Russian registration of epitalon could be confirmed from an allowed source.

Source: govinfo.gov (source dated 2026-10-30)

In sport: Epithalon is not named on the WADA Prohibited List for 2026 or 2027. Class S0 prohibits, at all times, any substance not covered elsewhere on the List that has no current approval by any government health regulator for human therapeutic use. The 2027 List adds peptides as a named example, and WADA's explanatory note says a peptide may still be prohibited even if it is not named. No approval for epithalon was found anywhere, so S0 applies unless an approval exists somewhere. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
Epithalon lengthens telomeres and reverses ageing.Telomere lengthening has been shown only in cells grown in the lab, including cancer cells in a 2025 study. No study has shown it lengthens telomeres or slows ageing in people, and the FDA flagged telomere lengthening as a possible cancer concern. Source: pubmed.ncbi.nlm.nih.gov
It extends lifespan.In the developer's mouse study, average lifespan did not change; only the longest-lived animals lived somewhat longer. In rats under standard lighting, lifespan did not change at all. The human reports of fewer deaths used the cattle extract epithalamin, not epithalon. Source: pubmed.ncbi.nlm.nih.gov
Decades of human use in Russia prove it is safe.The FDA found no clinical studies assessing epithalon's safety in people. The long-term human studies used epithalamin, and the epithalon studies were small and short. Source: fda.gov
It restores melatonin and improves sleep.Small studies reported changes in melatonin or its breakdown products, but none measured sleep, and in isolated rat pineal glands it did not raise melatonin. The FDA found no evidence it works for insomnia. Source: fda.gov
It prevents cancer.Fewer tumours were reported in some mouse and rat studies from the developer's group. The FDA said these studies were too short, used one dose and only female animals, and that continuous exposure could in theory promote cancer. Source: fda.gov
The US government approved or legalised epithalon in 2026.No. It remains unapproved. HHS published a draft, non-binding policy saying it would not take action against limited compounding of injectable epitalon acetate under conditions, after FDA staff had recommended against it. Source: govinfo.gov

What a genuine lab report should show

  • Identity by mass spectrometry: the free peptide Ala-Glu-Asp-Gly (C14H22N4O9) should match 390.35 g/mol. The acetate salt has a formula weight of 450.40 g/mol, so a report should say which form was tested.
  • Sequence confirmation, for example by tandem mass spectrometry (MS/MS): the same four amino acids in a different order have the same mass, so a mass match alone does not prove the sequence.
  • Purity by HPLC with individual impurities identified. The FDA criticised certificates that gave only a total-impurity figure and the largest single impurity.
  • Tests for bacterial toxins (endotoxin) and microbial contamination (bioburden). The FDA found these missing from the certificates it reviewed; the HHS draft policy expects them.
  • Residual solvents, elemental impurities and water content, plus a lot number, test date, named laboratory and the name of the original manufacturer.

How to read a lab report

What is not known

  • When epithalon was first made: the FDA briefing document says the late 1980s in one section and 1999 in another.
  • Whether epithalon or epithalamin was ever registered as a medicine in Russia. No record from an allowed source was found, and the FDA's country check did not include Russia.
  • PubChem lists epithalamin as a synonym for epitalon, but the FDA treats them as different substances. Readers should not assume epithalamin results apply to epithalon.
  • The design of the 2011 Kiev study: its title mentions a 15-year follow-up and the pituitary gland, while the abstract describes three years of a pineal preparation, and its patients may overlap with a 2006 report.
  • Patient numbers for the retinitis pigmentosa study come from a 2026 review, not from the original paper, which was not opened.
  • The Ivko 2021 melatonin study is not indexed in PubMed and was not opened; its details come from the FDA briefing document.
  • Whether long-term or continuous use raises cancer risk. No adequate long-term animal or human study exists.
  • The advisory committee's vote count: HHS says the committee voted in favour of inclusion; trade press reported 7 to 4 with one abstention, but no FDA minutes were read.
  • The HHS appendices were read from an Internet Archive capture dated 15 November 2026 because hhs.gov refuses automated access. Whether the draft policy has been finalised, and the FDA's final 503A decision, were still open when this page was researched.

Sources

All 21 sources
  1. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (2003). pubmed.ncbi.nlm.nih.gov
  2. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025). pubmed.ncbi.nlm.nih.gov
  3. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-GLy) on melatonin secretion by the pineal gland of young and old rats (2003). pubmed.ncbi.nlm.nih.gov
  4. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice (2003). pubmed.ncbi.nlm.nih.gov
  5. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice (2002). pubmed.ncbi.nlm.nih.gov
  6. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes (2007). pubmed.ncbi.nlm.nih.gov
  7. Peptides of pineal gland and thymus prolong human life (2003). pubmed.ncbi.nlm.nih.gov
  8. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up (2011). pubmed.ncbi.nlm.nih.gov
  9. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people (2007). pubmed.ncbi.nlm.nih.gov
  10. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (2002). pubmed.ncbi.nlm.nih.gov
  11. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence (2026). pubmed.ncbi.nlm.nih.gov
  12. FDA briefing document on epitalon-related bulk drug substances, dated 12 May 2026. fda.gov
  13. FDA Pharmacy Compounding Advisory Committee agenda, 23 and 24 July 2026. fda.gov
  14. FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026). fda.gov
  15. FDA: 503A nominated substances by category, updated 14 May 2026. fda.gov
  16. Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement-discretion policy notice. govinfo.gov
  17. HHS 503A peptide enforcement-discretion policy, Appendices A and B (read from an Internet Archive capture of 15 November 2026). hhs.gov
  18. WADA: 2026 Prohibited List. wada-ama.org
  19. WADA: 2027 Prohibited List. wada-ama.org
  20. WADA: 2027 Prohibited List, summary of major modifications and explanatory notes. wada-ama.org
  21. PubChem: Epitalon, CID 219042. pubchem.ncbi.nlm.nih.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.